Supernus Pharmaceuticals (SUPN) Non-Current Debt (2011 - 2021)
Supernus Pharmaceuticals' (SUPN) quarterly Non-Current Debt came in at $379.3 million in Q4 2021, up 4655.51% on a QoQ basis from $8.0 million in Q1 2013.
Supernus Pharmaceuticals (SUPN) Non-Current Debt (2011 - 2021) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 4 years of Non-Current Debt data on file, last reported at $379.3 million in Q4 2021.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $379.3 million in Q4 2021; TTM through Dec 2021 was $379.3 million, a N/A change from a year earlier, with the FY2021 full-year figure at $379.3 million, changed N/A from the prior year.
- Non-Current Debt for Q4 2021 stood at $379.3 million, up from $8.0 million in the prior quarter.
- Over the last five years, Non-Current Debt for SUPN reached as high as $379.3 million in Q4 2021 and fell as low as $379.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Supernus Pharmaceuticals | 2.72 Bn | 2.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 379.25 Mn |
| Mar 31, 2013 | 7.98 Mn |
| Dec 31, 2012 | 11.09 Mn |
| Sep 30, 2012 | 14.12 Mn |
| Jun 30, 2012 | 17.06 Mn |
| Mar 31, 2012 | 19.93 Mn |
| Dec 31, 2011 | 22.71 Mn |